Characterization of antibodies induced by vaccination with Hepatitis C virus envelope glycoproteins

Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 were used with MF59 adjuvant as a candidate vaccine for a phase 1 safety and immunogenicity trial. Ten of 41 vaccinee serum samples displayed a neutralization titer of ⩾1:20 against vesicular stomatitis virus (VSV)-HCV pseudotype, 15 of 36 ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Ranjit, Meyer, Keith, Banerjee, Arup, Basu, Arnab, Coates, Stephen, Abrignani, Sergio, Houghton, Michael, Frey, Sharon E., Belshe, Robert B.
Formato: Texto
Lenguaje:English
Publicado: University Chicago Press 2010
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931414/
https://www.ncbi.nlm.nih.gov/pubmed/20677942
http://dx.doi.org/10.1086/655902
Descripción
Sumario:Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 were used with MF59 adjuvant as a candidate vaccine for a phase 1 safety and immunogenicity trial. Ten of 41 vaccinee serum samples displayed a neutralization titer of ⩾1:20 against vesicular stomatitis virus (VSV)-HCV pseudotype, 15 of 36 serum samples tested had a neutralization titer of ⩾1:400 against human immunodeficiency virus (HIV)-HCV pseudotype, and 10 of 36 serum samples tested had a neutralization titer of ⩾1:20 against cell culture-grown HCV genotype 1a. Neutralizing serum samples had increased affinity levels and displayed >2-fold higher specific activity levels to well-characterized epitopes on E1/E2, especially to the hypervariable region 1 of E2.

Ejemplares similares